News Breaks |
|
|
| January 8, 2013 |
| 08:02 EDT |  | CBST, SNY | Cubist to appoint Tom DesRosier as SVP, Chief Legal Officer
Cubist Pharmaceuticals (CBST) announced that Thomas J. DesRosier will be joining the company as SVP, Chief Legal Officer and Secretary. Mr. DesRosier is currently SVP, General Counsel North America of Sanofi (SNY), a position he assumed following the acquisition by Sanofi of Genzyme Corporation in 2011 where he served as Genzyme’s SVP, Chief Legal Officer. Mr. DesRosier will report to Cubist CEO Mike Bonney. |
|
|
News For CBST;SNY From The Last 14 Days Check below for free stories on CBST;SNY the last two weeks. |
|
|
| May 21, 2013 |
| 10:00 EDT |  | CBST | On The Fly: Analyst Upgrade Summary
 Subscribe for More Information |
|
| 07:44 EDT |  | SNY | Sachs Associates to host a forum
Subscribe for More Information |
|
| 07:17 EDT |  | CBST | Cubist price target raised to $63 from $53 at RBC Capital
Subscribe for More Information |
|
| 06:33 EDT | | CBST | Cubist upgraded to Hold from Sell at Cantor
Subscribe for More Information |
|
| May 20, 2013 |
| 17:26 EDT | | SNY | Regeneron, Genentech, Sanofi enter into 'Zaltrap agreement'
Subscribe for More Information |
|
| 15:56 EDT | | CBST | Cubist move higher attributed to patent construction in suit against Hospira
Subscribe for More Information |
|
| 15:42 EDT |  | CBST | Cubist options active on speculation of a favorable patent ruling
Cubist (CBST) June 55 calls and June 47 puts are active on total call volume of 3K contracts (3K puts). June call option implied volatility is at 37, August is at 40; compared to its 26-week average of 36 according to Track Data. Active option volume suggests traders taking positions for movement on speculation of a favorable patent ruling vs.Hospira (HSP). |
|
| 15:28 EDT |  | CBST | Rumor: Cubist up on speculation of a favorable patent ruling vs.Hospira
|
|
| 11:27 EDT | | SNY | Appeals court reverses, remands patent ruling in Sanofi suit against Mylan, Teva
Subscribe for More Information |
|
| May 17, 2013 |
| 08:03 EDT | | SNY | Sanofi reports positive topline results from pivotal Phase III Jakarta study
Subscribe for More Information |
| |
| 05:51 EDT | | CBST | Stocks with implied volatility movement; CBST CELG
Subscribe for More Information |
|
| 05:18 EDT | | SNY | Sanofi says JAK2 inhibitor for myelofibrosis met primary endpoint
Subscribe for More Information |
|
| May 16, 2013 |
| 07:29 EDT | | CBST | Leerink to host a bus tour
Boston Biopharma Bus Tour travels throughout Boston on May 16-17. |
|
| May 15, 2013 |
| 17:46 EDT | | CBST | SAC Capital gives quarterly update on stakes
NEW STAKES: Discovery (DISCA), Liberty Global (LBTYA), Liberty Media (LMCA), Norwegian Cruise Line (NCLH), and Cubist (CBST). INCREASED STAKES: Suncor (SU), EQT Corporation (EQT), Amazon.com (AMZN), Visa (V), and GNC Holdings (GNC). DECREASED STAKES: News Corp. (NWSA), Facebook (FB), Sherwin-Williams (SHW), and Avago (AVGO). LIQUIDATED STAKES: Coach (COH), Dover (DOV), and Virgin Media (VMED), . |
|
| 16:00 EDT | | CBST | Optimer calls active following takeover report
Optimer (OPTR) May and June 17 calls are active on 5,600 contracts (500 puts) according to Track Data. Traders are taking positions for large price movement on Cubist (CBST) offered to buy the company for $20 per share, Reuters says. |
|
| 15:54 EDT | | CBST | Optimer up 12.5%, to $16.03 after Reuters report Cubist offered $20 per share
Subscribe for More Information |
|
| 15:53 EDT | | CBST | Cubist offered to buy Optimer for $20 per share, Reuters says
Subscribe for More Information |
|
| 15:16 EDT | | SNY | Sanofi systemic sclerosis treatment designated for orphan drug status
Subscribe for More Information |
|
| 05:39 EDT | | SNY | Sanofi, Regeneron announce patient enrollment in two Phase 3 trials
Subscribe for More Information |
|
| May 13, 2013 |
| 16:53 EDT |  | CBST | Optimer gets bids from AstraZeneca, Cubist, Astellas, Bloomberg says
Optimer (OPTR) has received first round bids from AstraZeneca (AZN), Cubist (CBST), and Astellas, reports Bloomberg, citing people familiar with the matter. Shares of Optimer spiked higher following the report, closing up $1.85, or 14.44%, to $14.66. The report notes the company disclosed almost three months ago it was exploring its strategic options. Reference Link |
| |
|
|
|
|
